Literature DB >> 3894969

First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion.

S Srikanta, O P Ganda, A Rabizadeh, J S Soeldner, G S Eisenbarth.   

Abstract

In a prospective study to evaluate the prevalence and predictive potential of circulating islet-cell antibodies, we have screened 1723 "normal" first-degree relatives (parents, siblings, and offspring) of patients with insulin-dependent diabetes mellitus. The prevalence of islet-cell antibodies on initial screening was 0.9 per cent (16 of 1723). Over a maximal follow-up period of two years, insulin-dependent diabetes mellitus developed in 2 of 16 relatives with islet-cell antibodies and in 1 of 1707 without antibodies. In addition, 6 of 12 nondiabetic relatives with islet-cell antibodies had abnormally low insulin responses--below the third percentile in 6 and below the first percentile in 4--on their initial intravenous glucose challenge. Thus, prospective islet-cell antibody screening of high-risk first-degree relatives, in combination with intravenous glucose-tolerance testing, is capable of identifying immunologically abnormal persons with profoundly diminished beta-cell function, who are presumably at increased risk of insulin-dependent diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894969     DOI: 10.1056/NEJM198508223130801

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  70 in total

Review 1.  The differentiation of the immune system towards anti-islet autoimmunity. Clinical prospects.

Authors:  C Boitard
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

2.  Escaping insulin dependent diabetes.

Authors:  R D Leslie; D A Pyke
Journal:  BMJ       Date:  1991-05-11

3.  Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays.

Authors:  E Bonifacio; C Boitard; H Gleichmann; M A Shattock; J L Molenaar; G F Bottazzo
Journal:  Diabetologia       Date:  1990-12       Impact factor: 10.122

4.  Immunotherapy in pre-type 1 diabetes mellitus.

Authors:  J F Bach; J Dupré; G S Eisenbarth; L C Harrison; N K Maclaren; J Nerup; P Pozzilli
Journal:  Diabetologia       Date:  1990-12       Impact factor: 10.122

5.  No association between islet cell antibodies and Coxsackie B, mumps, rubella and cytomegalovirus antibodies in non-diabetic individuals aged 7-19 years.

Authors:  W A Scherbaum; W Hampl; P Muir; M Glück; J Seissler; H Egle; H Hauner; B O Boehm; E Heinze; J E Banatvala
Journal:  Diabetologia       Date:  1991-11       Impact factor: 10.122

6.  The use of FK 506 in new-onset type I diabetes in man.

Authors:  P B Carroll; A G Tzakis; C Ricordi; H R Rilo; K Abu-Elmagd; N Murase; Y J Zeng; R Alejandro; D Mintz; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

7.  Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes.

Authors:  T R Hall; J W Thomas; C J Padoa; C Torn; M Landin-Olsson; E Ortqvist; C S Hampe
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

8.  Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes.

Authors:  Polly J Bingley; Diane K Wherrett; Ann Shultz; Lisa E Rafkin; Mark A Atkinson; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2018-04       Impact factor: 19.112

9.  Auto-immunity in children with diabetes mellitus and in their relatives.

Authors:  R Lorini; D Larizza; C Livieri; V Cammareri; A Martini; A Plebani; D Zanaboni; F Severi
Journal:  Eur J Pediatr       Date:  1986-08       Impact factor: 3.183

10.  Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes.

Authors:  K Decochez; I Truyen; B van der Auwera; I Weets; E Vandemeulebroucke; I H de Leeuw; B Keymeulen; C Mathieu; R Rottiers; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.